[go: up one dir, main page]

EA201400950A1 - METHODS OF DISTRIBUTING COMPLETE-INHIBITING MEDICINES AMONG PATIENTS OBTAINING THE COMPLETE INHIBITOR - Google Patents

METHODS OF DISTRIBUTING COMPLETE-INHIBITING MEDICINES AMONG PATIENTS OBTAINING THE COMPLETE INHIBITOR

Info

Publication number
EA201400950A1
EA201400950A1 EA201400950A EA201400950A EA201400950A1 EA 201400950 A1 EA201400950 A1 EA 201400950A1 EA 201400950 A EA201400950 A EA 201400950A EA 201400950 A EA201400950 A EA 201400950A EA 201400950 A1 EA201400950 A1 EA 201400950A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complete
patients
methods
distributing
inhibitor
Prior art date
Application number
EA201400950A
Other languages
Russian (ru)
Inventor
Леонард Белл
Original Assignee
Алексион Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алексион Фармасьютикалс, Инк. filed Critical Алексион Фармасьютикалс, Инк.
Publication of EA201400950A1 publication Critical patent/EA201400950A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/041—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к способам разрешения распространять комплемент-ингибирующие лекарственные средства среди пациентов с комплемент-ассоциированным нарушением, гарантирующим осведомленность пациентов о возможной опасности прекращения приема указанных лекарственных средств. Получена база данных, содержащая информацию о пациенте, в том числе о проявлении нежелательных клинических явлений после прекращения лечения с применением конкретного лекарственного средства. Информация в базе данных собрана и может быть предоставлена. Пациентам делают предупреждение в отношении нежелательных явлений, которые могут возникать при прекращении лечения с помощью конкретных комплемент-ингибирующих лекарственных средств.The invention relates to methods for allowing the distribution of complement-inhibiting drugs among patients with a complement-associated disorder, ensuring that patients are aware of the possible danger of discontinuing these medicines. A database containing information about the patient, including the manifestation of undesirable clinical events after cessation of treatment with the use of a specific drug, was obtained. Information in the database is collected and can be provided. Patients are cautioned against adverse events that may occur when treatment is discontinued with specific complement-inhibiting drugs.

EA201400950A 2012-03-16 2012-03-16 METHODS OF DISTRIBUTING COMPLETE-INHIBITING MEDICINES AMONG PATIENTS OBTAINING THE COMPLETE INHIBITOR EA201400950A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/029499 WO2013137912A2 (en) 2012-03-16 2012-03-16 Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor

Publications (1)

Publication Number Publication Date
EA201400950A1 true EA201400950A1 (en) 2014-12-30

Family

ID=49161929

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400950A EA201400950A1 (en) 2012-03-16 2012-03-16 METHODS OF DISTRIBUTING COMPLETE-INHIBITING MEDICINES AMONG PATIENTS OBTAINING THE COMPLETE INHIBITOR

Country Status (6)

Country Link
EP (1) EP2825989A4 (en)
CN (1) CN104205155A (en)
EA (1) EA201400950A1 (en)
HK (1) HK1204693A1 (en)
IL (1) IL234680A0 (en)
WO (1) WO2013137912A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010837A8 (en) 2013-11-13 2020-04-22 Shire Viropharma Inc use of a composition comprising a c1-esterase inhibitor (c1-inh), pharmaceutical composition comprising the same and its kits
CN105260974A (en) * 2015-09-10 2016-01-20 济南市儿童医院 Method and system for generating electronic case history with informing and signing functions
CN115177291B (en) * 2022-08-01 2023-11-10 首都医科大学附属北京朝阳医院 Methods and devices for identifying acquired myasthenia in intensive care units

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US20040117126A1 (en) * 2002-11-25 2004-06-17 Fetterman Jeffrey E. Method of assessing and managing risks associated with a pharmaceutical product
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US8478605B2 (en) * 2006-07-17 2013-07-02 Walgreen Co. Appropriateness of a medication therapy regimen
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
WO2010054403A1 (en) * 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity

Also Published As

Publication number Publication date
HK1204693A1 (en) 2015-11-27
EP2825989A2 (en) 2015-01-21
CN104205155A (en) 2014-12-10
WO2013137912A3 (en) 2014-05-01
IL234680A0 (en) 2014-11-30
EP2825989A4 (en) 2016-01-06
WO2013137912A2 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
CL2016002132A1 (en) Use of an amount of laquinimod, which is used to prepare a medication to treat a human patient affected with multiple sclerosis or who has a clinically isolated syndrome; a package, an amount of laquinimod and a pharmaceutical composition thereof.
MX2015006234A (en) Use of akkermansia for treating metabolic disorders.
EA201591166A1 (en) AUTOTAXIN INHIBITORS
BR112015009948A8 (en) Activin-actrii antagonists, uses thereof for treating bone diseases and other disorders, and method for monitoring the effectiveness of treating or preventing a bone disease and other disorders
UA117103C2 (en) Glucagon analogues
BR112015018168A2 (en) soft rock inhibitors
EA201590654A1 (en) COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON'S DISEASE
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
MX386251B (en) NOVEL HIGH-PENETRATION DRUGS AND THEIR COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASES.
BR112012022552A8 (en) use of fenoterol and fenoterol analogs in the treatment of gliobastomas and astrocytomas and pharmaceutical composition comprising said compounds
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MX2017004772A (en) Compositions and methods for physiological delivery using cannabidiol.
EA201590797A1 (en) PREPARATIONS WITH THE MODIFIED PROBE RELEASE
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
EA201501164A1 (en) SOLID PHARMACEUTICAL MEDICINE FORM
EA201400950A1 (en) METHODS OF DISTRIBUTING COMPLETE-INHIBITING MEDICINES AMONG PATIENTS OBTAINING THE COMPLETE INHIBITOR
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
JP2013520447A5 (en)
EP3020395A4 (en) METHOD FOR PREPARING LINGUAL MICRO-TABLET OF TRADITIONAL CHINESE MEDICINE AND LINGUAL MICRO-COMPRESSED OF TRADITIONAL CHINESE MEDICINE PREPARED USING THE METHOD
BR102012028120B8 (en) USE OF ONE OR MORE INGENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND DRUG
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
EA201301275A1 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF PREVENTION AND TREATMENT OF THE ADHESIVE PROCESS
BR112015007095A8 (en) dihydro-6-azafenalene derivatives for the treatment of snc, oncological diseases and related disorders, pharmaceutical composition comprising them and use of said derivatives
BR112017007031A2 (en) pharmaceutical composition for subcutaneous administration, method of treating a patient suffering from trauma or blood clotting disease, kit of parts, and dosage form of a pharmaceutical composition